Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | PRKCA | P17252 | 4/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.72 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997507 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL11782897 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL4862128 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18010946 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL345928 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL21472154 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL25272152 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL6014563 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL19285724 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL18613715 | 1.00 | ALDH1A1 (0.84) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | disclosed |
| EP-4230619-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-23 | — | — | EP | disclosed |
| US-11648240-B2 | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | CELLIX BIO PRIVATE LTD (IN) | 2023-05-16 | — | — | US | disclosed |
| US-11648240-B2 | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | CELLIX BIO PRIVATE LTD (IN) | 2023-05-16 | — | — | US | disclosed |
| US-11648240-B2 | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | CELLIX BIO PRIVATE LTD (IN) | 2023-05-16 | — | — | US | disclosed |
| WO-2023031755-A1 | FORMULATIONS, COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEURODEGENERATIVE DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-03-09 | — | — | WO | disclosed |
| US-11555007-B2 | Compositions and methods for the treatment of neurological diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-01-17 | — | — | US | disclosed |
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-11-01 | — | — | US | disclosed |
| US-20220340551-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-27 | — | — | US | disclosed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | disclosed |
| US-11220493-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-11 | — | — | US | disclosed |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-20210032194-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032194-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-04 | — | — | US | disclosed |
| EP-3761970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Cellix Bio Private Limited (IN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| EP-3581566-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2019-12-18 | — | — | EP | disclosed |
| WO-2019186357-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648240-B2 | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | MTNR1A, MTNR1B, MCOLN3 | ALDH1A1 4025/4885LMNA 403/4885PRKCA 4136/4885 |
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | ALDH1A1 3531/4885LMNA 2173/4885PRKCA 3565/4885 |
| US-11220493-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | ALDH1A1 3531/4885LMNA 2173/4885PRKCA 3565/4885 |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | ALDH1A1 3531/4885LMNA 2173/4885PRKCA 3565/4885 |
| US-11555007-B2 | Compositions and methods for the treatment of neurological diseases | SCNN1G, PMP22, TTR | ALDH1A1 2697/4885LMNA 1038/4885PRKCA 3802/4885 |
| US-20220340551-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | ALDH1A1 3531/4885LMNA 2173/4885PRKCA 3565/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | ALDH1A1 2390/4885LMNA 16/4885PRKCA 4135/4885 |
| US-20210032194-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SCNN1G, PMP22, TTR | ALDH1A1 2697/4885LMNA 1038/4885PRKCA 3802/4885 |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | ALDH1A1 3531/4885LMNA 2173/4885PRKCA 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.